Compare Novavax Inc (NVAX) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard S&P 500 ETF — how do they compare? Novavax Inc trades at $8.09 (market cap $1.30B), while Vanguard S&P 500 ETF trades at $687.16. The key difference: Vanguard S&P 500 ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | VOO | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $11.19 | $698.29 |
52-Week Low | $6.22 | $571.45 |
Enterprise Value | $800.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
VOO, the Vanguard S&P 500 ETF, trades at $682.20, down slightly by 0.14% over 24 hours. Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. The ETF recently surpassed $1.0 trillion in assets under management, reflecting strong institutional confidence. A dividend of $1.96 is scheduled for payment on June 30, 2026.
The outlook for VOO is mixed; its low-cost, diversified exposure to the S&P 500 offers long-term growth potential, but current technical weakness and elevated market valuations pose near-term risks. Investors should weigh the ETF's historical resilience against potential volatility from economic shifts or sector rotations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
